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ancer has overtaken cardiovascular disease as
the leading cause of death in individuals under
the age of 65 in the general population, but it is
still overshadowed by cardiovascular disease in
those with diabetes. People with type 2 diabetes are
nonetheless more likely to develop cancer—and to die
from it—than members of the general population, so
cancer should be numbered among the complications of
diabetes (1). Furthermore, the number of cancer victims
with diabetes will inevitably rise in proportion to our
success in combating vascular disease in the diabetic
population.
How can the increased cancer risk in diabetes be
explained? To begin with, it should be noted that obesity,
insulin resistance, and/or increased levels of IGF-1 and
insulin are strongly associated with most (but not all) of
the diabetes-related cancers in the nondiabetic population
(1). This suggests that hyperglycemia does not play an
essential role in the pathogenesis of these tumors, but
does not exclude the possibility that it might have second-
ary effects such as enhanced tumor growth or resistance to
anti-tumor therapy. IGF-1 and insulin offer a more plausi-
ble mechanistic explanation for the overlapping risk of
cancer in the nondiabetic and diabetic populations. Both
hormones are mitogenic (but not mutagenic), both are
present at high levels in insulin-resistant states, and their
receptors are overexpressed on the surface of cancer cells
associated with diabetes. They thus have the potential to
act as tumor growth factors in vivo as well as in vitro (2,3).
On this argument, which we will refer to as the insulin
supply hypothesis, drugs used to treat diabetes might
inﬂuence the risk of cancer by modulating the insulin/IGF
axis (1).
There is, however, a possible alternative explanation for
the increased risk of cancer in diabetes, which we refer to
as the glucose supply hypothesis. Although hyperglycemia
clearly cannot account for epidemiologic associations
seen in the nondiabetic population, as noted above, cancer
cells are characterized by their high metabolic activity and
avid glucose requirement (4). It would therefore be logical
to speculate that tumor growth might be regulated by
glucose availability (4,5). Support for this proposal comes
from the well-established observation that cancer risk
increases in proportion to A1C in diabetes (6,7). Further-
more—and given that patients with poor glucose control
are more likely to be offered insulin treatment—it is
reasonable to hypothesize that the reported associations
between insulin treatment and cancer risk in diabetes
might be driven by high glucose levels rather than any
direct effect of insulin. On this hypothesis, well-controlled
diabetes might be expected to delay tumor growth in those
with preclinical cancers, relative to those with poorly
controlled diabetes. This issue of Diabetes contains an
article by Yang et al. (5) that sets out to evaluate the
relative risks of hyperglycemia and insulin therapy in
patients with type 2 diabetes.
Before reviewing their ﬁndings, we should pause to
consider the potential limitations of the tools available.
How do we evaluate the potential of diabetes therapies—
for harm or for good—in relation to the increased risk of
certain types of cancer? The difﬁculties are legion. The
risks of cancer vary widely with age, sex, and geographical
region, greatly complicating comparisons between one
study population and another. The biological features of
cancer vary in relation to their tissue of origin, and global
measures of cancer risk may therefore mask the potential
impact of a speciﬁc therapeutic agent upon a speciﬁc type
of cancer. The latter type of analysis requires very large
sample sizes, limiting the relevance of controlled clinical
trials, which are the gold standard for this type of com-
parison. Patients typically receive multiple therapies for
diabetes, either sequentially or concurrently, making it
difﬁcult to dissect out the inﬂuence of any given medica-
tion, especially when escalating doses may also need to be
taken into consideration. Even assuming all this can be
done, correction still needs to be made for other con-
founders, which might in themselves account for the
observed effects.
Which brings us to one further layer of complexity: the
emerging possibility that some therapies used for diabetes
could modulate cancer risk independent of their effects
upon circulating insulin and glucose. This is linked to a
growing awareness that pathways involved in cell metab-
olism and cell growth are inextricably enmeshed, and that
our attempts to lower blood glucose may have unpredict-
able effects upon cell proliferation and growth. Hence,
metformin and the thiazolidinediones are currently in trial
as anti-tumor agents (8). Conversely, the possibility has
been raised that the GLP-1–based therapies may promote
the growth of pancreatic duct cells, causing duct hyper-
plasia, overt or subclinical pancreatitis, and potentially
carcinoma of the pancreas (9).
When confronted with all these complexities, it is easy
to sympathize with those who consider observational
studies part of the problem rather than part of the solution.
Such cynicism is clearly justiﬁed when observational
studies are poorly conducted or overinterpreted. On the
other hand, properly conducted and sensibly interpreted
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future solution, bearing in mind that the information we
require may never be available from controlled clinical
trials. The obvious limitation of descriptive studies, how-
ever, is that they describe but do not necessarily explain.
How then do we judge the article by Yang et al. (5)? The
authors have employed a “new users” cohort design and
data from the well-characterized Hong Kong Diabetes
Registry, concluding that better glucose control and insu-
lin use are each associated with a reduced risk of cancer in
Chinese patients with type 2 diabetes. The authors make
use of several methodologies intended to improve the
inference of causality between these exposures (blood
glucose level and use of exogenous insulin) and cancer
incidence. The new users design is stated to be a strength
given that it avoids potential biases associated with com-
parisons of prevalent insulin users within the cohort. Even
so, the article demonstrates some of the difﬁculties in-
volved in disentangling these exposures and understand-
ing the role of individual therapies in modulating the
relationship between diabetes and cancer.
The ﬁndings from this study conﬁrm the previously
recognized association between hyperglycemia and in-
creased risk of cancer outcomes (incidence and mortality)
(6,7). This relationship resembles the one between hyper-
glycemia and macrovascular outcomes (incidence and
mortality) in type 2 diabetes in that the association is
strong and consistent, but it is not reversed when glucose
control is actually improved. Thus, the recent large-scale
randomized controlled trials of intensiﬁed glycemic con-
trol for type 2 diabetes observed no difference between
intensiﬁed and conventional treatment arms in terms of
secondary outcomes of cancer incidence or mortality
(10–16). This in turn might suggest that the relationship
between glucose level and cancer outcomes is not causal
but confounded by other factors such as insulin resistance
and/or hyperinsulinemia (among others) (2,3).
Yang et al. go on to conclude that exposure to exoge-
nous insulin is associated with a reduced risk of cancer
(hazard ratio 0.17 [95% CI 0.09–0.32]), with risk estimates
that are consistent regardless of how the cohorts were
analyzed. A pearl of wisdom often taught in introductory
epidemiology courses is that one should be wary of
implausibly low (or high) risk estimates. It seems some-
what improbable that simply exposing people with type 2
diabetes to insulin would reduce the risk of cancer by 83%,
especially since insulin treatment is typically offered to
patients with higher glucose levels, which the authors
found to be associated with increased cancer risk within
the same study design. This prompts further exploration of
the study design and data for alternative explanations
including the selection of the comparison groups, match-
ing and residual confounding.
The cohorts of new insulin users and matched nonusers
were selected from a larger cohort of over 7,000 patients in
the Hong Kong Diabetes Registry after exclusion of those
with type 1 diabetes or preexisting cancer. Further, in
pursuit of a “new users” design, 1,480 subjects with
previous insulin use were also appropriately excluded. A
propensity score for insulin exposure was built on a set of
physiologic and clinical variables including age, smoking
status, duration of diabetes, and A1C. Given that age and
smoking status were matching variables, it is not clear
why they were also included in the propensity score,
whereas duration of diabetes or A1C were not. If A1C were
used as a matching variable, its relationship with cancer
incidence could not have been evaluated but, as pointed
out, this relationship is already well established.
The classiﬁcation of users and nonusers may also have
contributed to the extremely protective risk estimate since
to become a member of the insulin user cohort, subjects
would have had to survive, cancer free, long enough to
receive insulin. Moreover, using drug exposure variables
that are ﬁxed with time may introduce further bias into the
analyses. There is further scope for residual confounding
in the use of additional glucose-lowering treatments by
insulin users and nonusers and, given the available evi-
dence, it would have been helpful to control more strin-
gently for the exposures to these other agents. A stronger
approach would employ time-varying exposure deﬁnitions
and even a dose-response gradient, especially in the treat-
ment of type 2 diabetes, which tends to escalate over time.
Apart from these methodological considerations, a more
fundamental concern is that the authors postulate that the
observed protective effect of insulin is secondary to its
glucose-lowering action, but they do not document the
extent to which insulin actually lowered blood glucose.
This leaves the authors on the horns of a dilemma. If the
postulated protective effect of insulin as compared with
noninsulin therapies is due to glucose lowering, it follows
that patients on insulin would need to achieve lower
glucose levels than the comparator. From the evidence
presented, this was not the case. The alternative explana-
tion, i.e., that insulin directly suppressed tumor growth,
seems even more implausible.
In summary, Yang et al. have contributed to the rapidly
growing literature on the relationship between diabetes,
glucose-lowering therapy, and cancer, but these new data,
while useful in hypothesis generation, potentially give rise
to more problems than solutions. The results, unexpected
as they are in light of previous reports (17–19), are
however a useful reminder of the need to keep an open
mind in this complex and evolving area. The worst out-
come, in our view, would be for the reader to conclude
that observational studies are so intrinsically unreliable as
to be of no value at all. The best outcome would be for us
all to reach broader consensus as to how further studies
should be undertaken in this area, both in terms of
improved methodology and sharper focus on prespeciﬁed
outcomes for which we have a clear mechanistic hypoth-
esis. For all their limitations, observational studies provide
the best available evidence of potential harms in situations
such as this (20,21). It is of paramount importance, there-
fore, that such observational studies be appropriately
designed, rigorously conducted, and cautiously inter-
preted. We may be at the start of a long road when we try
to disentangle diabetes, diabetes therapy, and cancer, but
the road must be taken, wherever it might lead.
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